Combination therapies comprising administering radioimmunoconjugates and one or more checkpoint inhibitors.

The present invention relates to a set of antibodies which bind to antigens on target cells and which target radionuclides to said cells, and to methods of using the same. The antibodies each comprising a Fab binding to the target antigen fused at the C-terminus of the VH to the N-terminus of the Fc and a VH or VL binding to a radiolabelled compound. The VH or VL are fused at the C-terminus to the N-terminus of the Fc. VH and VL form an antigen binding site when the antibody binds via the scFv to the target antigen.

Aqueous formulations and kits of radiopharmaceutical compounds of general Formula (II) protected from radiolysis with stabilisers, such as L-methionine and gentisic acid, are disclosed, wherein the compounds are based on sarcophagine ligands coordinated to a radioisotope, such as 64-copper, and linked to a tetrazine group for reaction with tumour targeting antibodies having functional reactive groups such as trans-cyclooctene, processes of preparing said radioligand formulations, and uses thereof for radioimaging, diagnosing and treating cancer. ##STR00001##

Rigidified pentadentate chelating agents of Formulae (I) and (II), which are useful for the [Al.sup.18F].sup.2+ labelling of biomolecules are provided. The rigidified pentadentate chelating agents are used to form coordination complexes with [Al.sup.18F].sup.2+, which are particularly advantageous for use as tracers in molecular imaging techniques.

##STR00001##

Among the various aspects of the present disclosure is the provision of compositions of isotope-ligand complexes, methods of use thereof, and methods of chelating isotopes. The present disclosure also provides for methods for modulating ion channel transportation of radiopharmaceuticals. For example, the inhibition of radiopharmaceutical transport comprises administering an ion channel transport modulating or inhibiting agent (e.g., a calcium channel inhibitor) in an amount effective to inhibit gastrointestinal uptake.

##STR00001##

The present invention is directed to compounds and pharmaceutically acceptable salts thereof, immunoconjugates, radioimmunoconjugates thereof, pharmaceutical compositions containing said compounds and immunoconjugates, radioimmunoconjugates thereof, and the use of said compounds and immunoconjugates, radioimmunoconjugates thereof, in the treatment of neuroplastic diseases or disorders.

Low-molecular weight gadolinium (Gd)-based MR contrast agents for PSMA-specific T.sub.1-weighted MR imaging are disclosed. The (Gd)-based MR contrast agents exhibit high binding affinity for PSMA and exhibit specific T.sub.1 contrast enhancement at PSMA+ cells. The PSMA-targeted Gd-based MR contrast agents can be used for PSMA-targeted imaging in vivo. .sup.86Y-labeled PSMA-binding ureas also are provided, wherein the PSMA-binding ureas also are suitable for use with other radiotherapeutics.

A method of preparing a .sup.64Cu-BaBaSar-RGD.sub.2 solution is provided. The method includes lyophilizing a solution of BaBaSar-RGD.sub.2 and adding a .sup.64Cu solution to the lyophilized BaBaSar-RGD.sub.2.

Disclosed herein are methods preparing a purified, carrier-free 68Ga solution. Tire present disclosure also provides systems for preparing a purified, carrier-free 68Ga solution. The present disclosure also provides compositions comprising the purified, carrier-free 68Ga solutions disclosed herein. Also provided are methods of administering compositions of the present disclosure to a patient in need thereof, for example, for imaging a disease or disorder, such as cancer.

The present disclosure is generally related to methods, systems and devices for direct production of a radioisotope-based cancer treatment pharmaceutical directly from a corresponding non-radioactive drug molecule precursor by irradiating the non-radioactive drug molecule precursor using neutrons produced by an electronic neutron generator array or other neutron generator sources.